Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib in Asian Subjects With Advanced Solid Tumors
NCT02734433Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pexidartinib in solid tumor (advanced stage), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall Response Based on RECIST V1.1. Started Jun 2016; status: completed.
02
Drugs
pexidartinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02734433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734433.